Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

9 clinical studies listed.

Filters:

cGVHD

Tundra lists 9 cGVHD clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ACTIVE NOT RECRUITING

NCT06458127

Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease

This research study is evaluating the feasibility and acceptability of implementing a telehealth palliative care intervention in patients with moderate to severe chronic graft-versus-host disease.

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-06

1 state

Chronic Graft-versus-host Disease
Chronic GVHD
cGVHD
RECRUITING

NCT05919511

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-24

24 states

cGVHD
NOT YET RECRUITING

NCT07484113

IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD

A single-center, Phase 1, open-label, investigator-initiated clinical trial evaluating the safety, tolerability, and preliminary efficacy of sarilumab (anti-IL-6R) monotherapy as a rescue in adult patients with belumosudil-refractory chronic graft-versus-host disease (cGVHD).

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-19

cGVHD
NOT YET RECRUITING

NCT07476872

Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).

This study aims to evaluate the safety and efficacy of Gecacitinib in patients with steroid-refractory/dependent active chronic graft versus host disease (cGVHD).

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-17

cGVHD
HSCT
RECRUITING

NCT07253259

A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)

The goal of this clinical study is to evaluate the safety and efficacy of GT729 universal cell injection in the treatment of refractory or relapsed chronic graft-versus-host disease (cGVHD).

Gender: All

Ages: 18 Years - 65 Years

Updated: 2025-11-28

1 state

cGVHD
RECRUITING

NCT07246031

BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation

A Phase IIb open label study evaluates the safety and efficacy of repeat doses of BPC2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Haploidentical Stem Cell Transplantation (Haplo-SCT).

Gender: All

Ages: 18 Years - 65 Years

Updated: 2025-11-24

1 state

Graft -Versus-host-disease
aGVHD
Haploidentical Stem Cell Transplantation
+1
RECRUITING

NCT06920199

Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2

This study is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety, tolerability, changes and persistence of peripheral blood Treg cells, and pharmacodynamic characteristics of donor-derived Treg cell injection combined with recombinant human interleukin-2 in treating subjects with refractory cGVHD,and to preliminarily observe the efficacy of the study drugs in subjects with refractory cGVHD.

Gender: All

Ages: 18 Years - 70 Years

Updated: 2025-09-30

cGVHD
RECRUITING

NCT06663722

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

The purpose of this study is to see whether giving participants a combination treatment of Axatilimab and Extracorporeal Photopheresis (ECP) is effective against chronic Graft-versus-Host Disease (cGVHD).

Gender: All

Ages: 12 Years - Any

Updated: 2025-05-20

1 state

Chronic Graft Versus Host Disease
cGVHD
NOT YET RECRUITING

NCT06364319

Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD

The study plan aims to include patients who have been diagnosed with steroid-refractory chronic GVHD in the liver following allogeneic hematopoietic stem cell transplantation. After obtaining informed consent, the patients will be randomly assigned to either the Anti-CD25 rhMAb treatment group or the traditional treatment group. The objective is to assess the effectiveness and safety of Anti-CD25 rhMAb in the treatment of severe chronic GVHD affecting the liver.

Gender: All

Ages: 16 Years - 65 Years

Updated: 2024-04-15

cGVHD